After converting raw chemokine data (CXCL10, CCL2, CCL8, CCL19, CXCL11) into a combined IFN score, we observed significantly higher type I IFN scores overall in patients with AOSD compared with HCs (4.6 [4.2–5.1] vs 4.2 [3.9–4.4], median [IQR], P = 0.0015) and to patients with non–type I IFN‐dependent AIDs, such as FMF (P = 0.0003, 4.1 [3.9–4.3], median [IQR]). This evidence concerns the gene CCL19 and adult-onset Still disease.